Celanese Corporation — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless stated otherwise. Celanese is a global chemicals and specialty materials company, with Engineered Materials and Acetyl Chain segments. Financial statements are unaudited and prepared under U.S. GAAP.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / prior period |
|---|---|---|
| Net sales | $2.611 billion | $2.853 billion; down 8% |
| Gross profit | $554 million | $631 million |
| Operating profit | $210 million | $251 million; down 16% |
| Operating margin | 8.0% | 8.8% |
| Net earnings attributable to Celanese | $121 million | $91 million |
| Diluted EPS | $1.10 | $0.83 |
| Operating cash flow | $101 million | $(96) million |
| Capital expenditures | $137 million cash outflow | $164 million cash outflow |
| Cash and equivalents | $1.483 billion | $1.805 billion at Dec. 31, 2023 |
| Total debt | $13.457 billion | $13.684 billion at Dec. 31, 2023 |
Interest expense was $169 million, versus $182 million. The effective tax rate was 21%, unchanged year over year. Cash decreased by $322 million during the quarter. Operating cash flow improved by $197 million year over year, primarily from working-capital timing and lower net cash interest paid. The filing does not provide a company-defined free-cash-flow measure.
At March 31, current debt and short-term borrowings were $2.439 billion, compared with $1.383 billion at year-end; long-term debt was $11.018 billion, compared with $12.301 billion. Available borrowing capacity was $1.75 billion under the U.S. revolver and $201 million under the China facility. On May 8, 2024, the company drew $300 million on its U.S. revolver and used the proceeds and cash on hand to repay in full $473 million of 3.500% notes due that date. The company said it was in compliance with material financing covenants at quarter-end.
Material changes and segment results
- Engineered Materials: Sales fell 15.5% to $1.378 billion, reflecting a 12% volume decline, 2% lower pricing and 1% unfavorable currency impact. Operating profit declined 20.5% to $89 million; results included $37 million of accelerated depreciation related to the Uentrop closure. Equity earnings from affiliates increased to $49 million from $11 million.
- Acetyl Chain: Sales rose 0.9% to $1.261 billion as volume increased 11%, partly offset by 10% lower pricing. Operating profit declined 8.6% to $254 million, including $43 million of higher spending, principally Fairway Methanol turnaround costs and inventory effects.
- Consolidated sales were pressured by lower Engineered Materials volumes, customer destocking, competitive pricing and unfavorable currency. Higher Acetyl Chain volume partially offset these effects. Lower raw-material costs and interest expense, along with higher affiliate earnings, supported results.
- Net earnings included no discontinued-operations loss in Q1 2024, compared with a $3 million loss in Q1 2023. Other charges were $14 million, primarily restructuring, versus $23 million.
Outlook, management commentary and risks
- Management reported below-normal demand in several end markets, competitive conditions and continued pricing pressure. It expects demand challenges and pricing pressure to persist, partly offset by improving input costs during 2024. No full-year earnings or sales guidance is provided in the supplied filing text.
- Management expects 2024 capital expenditures of approximately $425 million. Certain capacity projects were reported on schedule; construction of the Bishop UHMW-PE debottleneck was delayed nine to 12 months. Clear Lake acetic acid expansion was commissioned in Q1; the Nanjing VAE unit started in Q2.
- Celanese is prioritizing deleveraging, has paused share repurchases and is evaluating additional cash-generation opportunities, including possible dispositions or asset monetizations. Management believes available liquidity is sufficient for operating, investment and financial obligations for the foreseeable future, while noting that cash generation may fall short of expectations.
- The company expects additional closure and shutdown costs through 2025 of approximately $36 million for Uentrop and $130 million for Mechelen. Mechelen operations are planned to cease in Q4 2024. Q1 included $42 million of Uentrop exit costs, including $37 million accelerated depreciation, and $8 million of Mechelen accelerated depreciation.
- Unconditional purchase obligations totaled $4.2 billion, including $530 million payable in 2024. Environmental remediation liabilities were $60 million. The company said its expected share of Lower Passaic River cleanup costs is less than 1% and not material; the related consent decree remained subject to public comment and court approval. Other litigation and environmental outcomes remain uncertain.
- Open tax audits include U.S., German, Canadian and Mexican matters. Management believes adequate tax provisions have been recorded, but an unfavorable resolution could materially affect results or cash flows in the period recorded. Other principal risks include end-market cycles, raw-material and energy price volatility, leverage and refinancing, integration of the acquired Mobility & Materials business, currency and interest-rate changes, supply disruptions, regulation and litigation.
Important facts for investors to verify
- Whether demand, destocking and pricing pressure improve or persist, particularly in Engineered Materials, and whether Acetyl Chain volume gains translate into profit growth.
- The trajectory of debt reduction, refinancing costs and liquidity after the May 2024 repayment of the 3.500% notes; also monitor the elevated current-debt balance reported at quarter-end.
- Actual closure costs and timing for Uentrop and Mechelen, and whether the planned $425 million 2024 capital program and delayed Bishop project remain on schedule.
- Cash-flow quality, including working-capital movements and reliance on receivables sales and factoring arrangements.
- Developments in tax audits, environmental proceedings and other contingencies, including approval of the Passaic River consent decree.